MedTrace Logo

Preservation of Beta-cell Function in Type 2 Diabetes Mellitus

NCT00232583 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2017-12-14

Study results available
· View outcomes & findings →

Summary

The study evaluates the rate beta-cell function decline in newly diagnosed type 2 diabetic patients on two different treatment regimens: insulin and metformin versus glyburide, metformin and pioglitazone.

Conditions

Interventions

DRUG

Metformin

Metformin 1000mg/BID

DRUG

Insulin

Insulin Novolg 70/30 per protocol titration

DRUG

Metfomin

Metformin 1000mg/BID

DRUG

Pioglitazone

Pioglitazone 45mg

DRUG

glyburide

Glyburide per protocol titration

Sponsors & Collaborators

  • University of Texas Southwestern Medical Center

    lead OTHER

Principal Investigators

  • Philip Raskin, MD · University of Texas

  • Ildiko Lingvay, MD · University of Texas

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-11-30
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00232583 on ClinicalTrials.gov